217
Participants
Start Date
December 10, 2021
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2027
ONO-4685
ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed
RECRUITING
New York-Presbyterian/Columbia University Irving Medical Center - Herbert Irving Comprehensive Cancer Center (HICCC), New York
RECRUITING
Memorial Sloan-Kettering Cancer Center, New York
RECRUITING
Roswell Park Cancer Institute, Buffalo
RECRUITING
Novant Health Presbyterian Medical Center, Charlotte
RECRUITING
Winship Cancer Institute of Emory University, Atlanta
RECRUITING
University of Alabama at Birmingham, Birmingham
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
Karmanos Cancer Institute, Detroit
RECRUITING
UT Southwestern Medical Center, Dallas
RECRUITING
MD Anderson, Houston
RECRUITING
City of Hope, Duarte
RECRUITING
University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center, Orange
RECRUITING
Stanford Cancer Institute, Palo Alto
RECRUITING
Oregon Health & Science University, Portland
RECRUITING
Yale Cancer Center, New Haven
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
Hackensack University Medical Center - John Theurer Cancer Center, Hackensack
Lead Sponsor
Ono Pharmaceutical Co. Ltd
INDUSTRY